Meta AnalysisID 6240
津力达颗粒联合二甲双胍治疗2型糖尿病：一项更新版系统评价和Meta分析
CRD42022312715
The purpose of this meta-analysis is to evaluate the efficacy and safety of jinlida granule combined with metformin in the treatment of type 2 diabetes, and to provide clinical evidence guidance.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6240
- Evidence Id
- 14798
- Core Evidence Id
- 14798
- Source Meta Analysis Id
- 6223
- Herb2 Meta Analysis Id
- HBMA006223
- Crd Id
- CRD42022312715
- Title
- Jinlida granules combined with metformin for type 2 diabetes: an updated systematic review and meta-analysis
- Review Question
- The purpose of this meta-analysis is to evaluate the efficacy and safety of jinlida granule combined with metformin in the treatment of type 2 diabetes, and to provide clinical evidence guidance.
- Study Type Included
- We include only published randomized controlled trials, ruled out any other types of articles.
- Condition Being Studied
- The Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 edition) pointed out that for type 2 diabetes (T2DM) with deficiency of both qi and yin, on the basis of the application of hypoglycemic drugs such as metformin, Jinlida granules can be added. In recent years, the number of randomized controlled trials in Jinlida granules combination with metformin for the treatment of type 2 diabetes continues to increase, therefore, it is necessary to conduct an updated meta-analysis to provide a more accurate evidence-based basis for clinical practice.
- Participant
- Participants were clearly diagnosed with type 2 diabetes, randomized controlled trials with type 2 diabetes as the primary disease to be treatedand, and the diagnostic criteria included: WHO 1999 Diagnostic Criteria and Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 Edition).
- Animal
- Human Disease Modelled
- Intervention
- The intervention group was oral jinlida granule plus metformin, and other types of hypoglycemic drugs were excluded.
- Comparator Control
- The control group received metformin orally.
- Main Outcome
- glycated hemoglobin(HbA1c)
- Outcome Measure
- Additional Outcome
- 1) fasting blood glucose(FBG); 2) 2 hours postprandial blood glucose(2hPG); 3) time in range(TIR); 4) adverse events(AEs)
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Humans; Hypoglycemic Agents; Metformin; jinlida
- Contact
- Fengya Zhu [email protected]
- Organisational Affiliation
- Chengdu University of TCM
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-02-23
- Registration Date
- 2022-03-26
- Anticipated Start Date
- 2022-03-01
- Anticipated Completion Date
- 2022-08-01
- Title Cn
- 津力达颗粒联合二甲双胍治疗2型糖尿病：一项更新版系统评价和Meta分析
- Title En
- Jinlida granules combined with metformin for type 2 diabetes: an updated systematic review and meta-analysis
- Bilingual Status
- complete